AbbVie (ABBV) February weekly 165 straddle into quarter results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. WCN
6. SPOT
7. FIX
8. BE
9. BMY
10. PNFP

Go back to AbbVie (ABBV) February weekly 165 straddle into quarter results

Abbvie (ABBV) PT Raised to $180 at Goldman Sachs

February 5, 2024 5:58 AM EST

Goldman Sachs analyst Chris Shibutani raised the price target on Abbvie (NYSE: ABBV) to $180.00 (from $173.00) while maintaining a Buy rating.

The analyst comments "4Q23 results and management's commentary on the FY24 and longer-term outlook strengthen our confidence in the potential for ABBV shares to continue to outperform. Across the company's Immunology... More

AbbVie (ABBV) tops Q4 earnings, revenue consensus estimate

February 2, 2024 8:37 AM EST

AbbVie (NYSE: ABBV) shares edged around 1% higher early Friday after the company reported earnings before the open, topping fourth-quarter profit and revenue expectations.

The American pharmaceutical company reported fourth-quarter adjusted earnings of $2.79 per share, $0.02 better than the analyst estimate of $2.77. Meanwhile, revenue... More